Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
GENESIS Pharma announces new partnership with Otsuka Pharmaceutical Europe Ltd. to market donidalorsen for hereditary angioedema in Central and Eastern Europe.
Tuesday, December 16, 2025Anixa Biosciences Inc a biotechnology company focused on the treatment and prevention of cancer today announced that it has completed the transfer of the Investigational New Drug application IND
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
Thursday, December 11, 2025Zealand Pharma AS a biotechnology company transforming the future of metabolic health today presents its strategy for redefining the nearterm future of weight management and its vision to establish leadership in metabolic health at its Capital Market...
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
Thursday, December 11, 2025Roche announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring This establishes Roches invitro diagnostics IVD menu as the broadest available for any automated mass spectrometry
Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia
Wednesday, December 10, 2025Tris Pharma Inc a commercialstage biopharmaceutical company focused on developing innovative therapies for unmet needs today announced that the US Food and Drug Administration FDA has accepted the companys New Drug Application NDA
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Tuesday, December 09, 2025Hikma Pharmaceuticals PLC Hikma the multinational pharmaceutical company today announces the launch of the firstofitskind readytouse vancomycin premix with roomtemperature stability under the brand name TYZAVAN
Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China
Tuesday, December 09, 2025Pillar Biosciences and AstraZeneca today announced an expansion of their existing laboratory access program for NGSbased kitted liquid biopsy tumor profiling to include China
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes
Friday, December 05, 2025LabGenius Therapeutics LabGenius a drug discovery company combining machine learning ML and highthroughput experimentation to optimise potential therapeutic antibodies today announced a second collaboration with Sanofi
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
Friday, December 05, 2025SCTbio a leading European CDMO specializing in GMP manufacturing for cellbased products and Fortrea a leading global contract research organization CRO today announced a strategic collaboration agreement between the two companies
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Thursday, December 04, 2025Eli Lilly and Company today announced that the US Food and Drug Administration FDA has granted approval to Jaypirca pirtobrutinib mg mg tablets for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Wednesday, December 03, 2025AstraZenecas New Drug Application NDA for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration FDA in the US for the treatment of adult patients with hardtocontrol
